Factual and Procedural Background
This appeal arises from a judgment of Judge Kitchin dated 15th October 2008 concerning the validity of an expired patent for a chiral antimicrobial compound known as levofloxacin, the S(-) enantiomer of ofloxacin. The patent in question was challenged on multiple grounds including novelty, obviousness, added matter, and insufficiency. The appellants, referred to as GUK, ultimately limited their appeal to two points: the obviousness of the patent over a prior disclosure known as Gerster IP and the validity of a supplementary protection certificate ("SPC") granted based on the patent. The case involves detailed consideration of patent validity and the interpretation of SPC legislation in relation to marketing authorisations for medicinal products.
Legal Issues Presented
- Whether the patent for levofloxacin was obvious in light of the prior disclosure Gerster IP.
- Whether the supplementary protection certificate (SPC) granted for levofloxacin was valid under the relevant SPC legislation, considering prior marketing authorisations for the racemic mixture of ofloxacin.
Arguments of the Parties
Appellant's Arguments
- On obviousness, the appellants argued that the skilled person would find it obvious to resolve the racemic mixture of ofloxacin into its enantiomers by applying the method disclosed in Gerster IP for flumequine, due to structural similarities of intermediates.
- Regarding the SPC, the appellants contended that levofloxacin was not a new active ingredient for SPC purposes because the earlier marketing authorisation for ofloxacin (the racemic mixture) should count as the first authorisation for levofloxacin, rendering the SPC invalid.
- They relied on case law including BASF, MIT, and Fusilade, as well as foreign decisions, to support their interpretation of SPC legislation.
Respondent's Arguments
- The respondent maintained that the patent was not obvious over Gerster IP due to significant structural differences between flumequine and ofloxacin, the unusual nature of the derivatising agent used, and the lack of common general knowledge about the relevant synthetic intermediates.
- They argued that the SPC was valid because levofloxacin was a novel and inventive active ingredient distinct from ofloxacin, and the prior marketing authorisations for ofloxacin did not constitute first authorisations for levofloxacin under the SPC legislation.
- The respondent rejected the applicability of foreign cases and asserted that the SPC legislation should be interpreted in line with EU law and policy aiming to protect genuine pharmaceutical innovations.
Table of Precedents Cited
| Precedent |
Rule or Principle Cited For |
Application by the Court |
| Generics v Lundbeck [2007] EWHC 1040 (Pat) |
Explanation of stereochemistry and patent claim construction regarding enantiomers and racemates. |
Used to clarify the distinction between claims to racemic mixtures and claims to individual enantiomers. |
| Conor v Angiotech [2008] UKHL 49 |
Clarification of the "obvious to try" test in obviousness analysis, requiring a fair expectation of success. |
Applied to assess whether the skilled person would have found it obvious to try the resolution method disclosed in Gerster IP. |
| Brugger v Medic-Aid [1996] R.P.C. 635 |
Obviousness of multiple routes and the order in which a skilled person might try them. |
Referenced to support that multiple obvious routes can exist but not all would be pursued relentlessly without sufficient motive. |
| Beloit v Valmet [1997] RPC 489 |
Definition and limits of common general knowledge in patent law. |
Used to determine what information the skilled person would have as common general knowledge relevant to the obviousness inquiry. |
| Raychem's Patent [1998] RPC 31 |
Extent of knowledge of the skilled person and the concept of common general knowledge including material readily available but not necessarily memorised. |
Applied to refine understanding of the skilled person's knowledge and its impact on obviousness. |
| Biogen v Medeva [1997] RPC 1 |
Appellate caution in overturning factual findings on obviousness. |
Guided the court's approach to reviewing the trial judge's evaluation of obviousness. |
| BASF (Case C-258/99, ECJ) |
Interpretation of "product" in SPC legislation concerning active substances and impurities. |
Distinguished from the present case to reject the appellants' argument that levofloxacin was merely an impurity in ofloxacin. |
| MIT (Case 431-04, ECJ) |
SPC refusal for slow-release form of a known active ingredient without new active ingredient status. |
Distinguished to show the present case involves a novel active ingredient (levofloxacin) unlike a mere new form. |
| Fusilade (Bundespatentgericht, 27.3.2000) |
SPC refusal for enantiomer when racemate patent and authorisation existed and resolution was straightforward. |
Applied to show that the present case differs because levofloxacin is subject to a separate patent and is a novel inventive product. |
| Lundbeck v Generics [2008] EWCA Civ 311 |
Patent claim construction and novelty tests for enantiomers. |
Referenced to support the novelty and inventive step of levofloxacin over prior art. |
| Synthon v SKB [2006] RPC HL |
Novelty test for patents based on the inevitable result test. |
Used to support the novelty of levofloxacin as a separate invention from the racemate. |
| Ortho-McNeil v Lupin Pharmaceutical (2009, US District Court) |
Patent extension provisions under U.S. law for enantiomers. |
Considered but found not directly relevant due to differing statutory language. |
Court's Reasoning and Analysis
The court began by examining the validity of the patent for levofloxacin, focusing on the obviousness attack limited to the Gerster IP disclosure. The court noted that the skilled person in 1985 was aware of ofloxacin as a racemic mixture and recognized the potential for differing biological activity between enantiomers, but the incentive to resolve the racemate was limited due to the difficulty and uncertain benefit.
The court applied the established legal test for obviousness derived from Article 56 of the EPC and the Windsurfing/Pozzoli framework, emphasizing that any formulaic approach (such as "obvious to try") must be applied with caution and always in light of the statutory question.
In assessing Gerster IP, the court accepted the trial judge’s findings that flumequine was no longer influential by 1985, and that structural differences between flumequine and ofloxacin, combined with the unusual derivatising agent used in Gerster IP, meant that it would not have been obvious to apply the disclosed resolution method to ofloxacin. The court also agreed that the skilled person would not have had the common general knowledge of the relevant synthetic intermediates to recognize the alleged similarity, and that the reaction’s success was unpredictable. The court found no error of principle in the judge’s balancing of these factors and upheld the validity of the patent.
Regarding the SPC, the court analyzed the legislative framework under Regulation 1768/92 and its sister Regulation 1610/96, considering the definitions of "product," "active ingredient," and "basic patent." It rejected the appellants' argument that the earlier marketing authorisations for ofloxacin constituted the first authorisation for levofloxacin, emphasizing that levofloxacin was a novel, inventive, and distinct active ingredient with its own marketing authorisation and patent protection.
The court distinguished relevant case law cited by the appellants, particularly noting that BASF and MIT involved different factual and legal contexts where the active ingredient was not novel or where the second authorisation was for a mere new form rather than a distinct active ingredient. The Fusilade decision was also distinguished on the basis that resolution was straightforward and there was no separate patent for the enantiomer in that case, unlike here.
The court concluded that the SPC was validly granted, reflecting the policy intention to protect genuine pharmaceutical innovations and not to extend protection unduly for minor variants or formulations.
Holding and Implications
The court DISMISSED the appeal, upholding both the validity of the patent for levofloxacin and the validity of the supplementary protection certificate (SPC) based on it.
The decision confirms that a patent for an enantiomerically pure compound can be validly distinguished from a patent for its racemic mixture and that the SPC framework protects such novel active ingredients with separate marketing authorisations. The ruling clarifies the application of obviousness principles in complex chemical cases and affirms the careful interpretation of SPC legislation to balance innovation incentives with legal certainty. No new precedent beyond the case’s facts was established, and the decision primarily affects the parties by maintaining the patent and SPC protections for the respondent’s product.